Filtering

OP19: Perinatal factors do not affect paediatric Inflammatory Bowel Disease risk: A Scottish nationwide cohort study using administrative health data 1981-2017ECCO'20 Vienna
Year: 2020
Authors: Christopher Burgess
OP21: Positivity thresholds of a total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring serviceECCO'20 Vienna
Year: 2020
Authors: Nicholas Alexander Kennedy
OP23: Efficacy and safety of vedolizumab SC in patients with Moderately to Severely active Crohn’s Disease: Results of the VISIBLE 2 studyECCO'20 Vienna
Year: 2020
Authors: Séverine Vermeire
OP24: A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s Disease and Ulcerative ColitisECCO'20 Vienna
Year: 2020
Authors: Shomron Ben-Horin
OP25: Biologics before surgery for IBD - Are they associated with post-operative infectious outcomes? Results from the National Surgical Quality Improvement Program Inflammatory Bowel Disease CollaborativeECCO'20 Vienna
Year: 2020
Authors: Stefan Holubar
OP26: The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in Ulcerative ColitisECCO'20 Vienna
Year: 2020
Authors: Marietta Iacucci
OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s Disease: Final results from the Phase 2 open-label extension studyECCO'20 Vienna
Year: 2020
Authors: Marc Ferrante
OP28: Gene expression (GE) values in a phase 2 trial of mirikizumab in Ulcerative Colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scoresECCO'20 Vienna
Year: 2020
Authors: Klaus Gottlieb
OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida RegistryECCO'20 Vienna
Year: 2020
Authors: Maria Chaparro
OP31: Meta–omics reveals microbiome driven proteolysis as a contributing ractor to severity of Ulcerative Colitis disease activityECCO'20 Vienna
Year: 2020
Authors: Parambir Dulai
OP33: Multi-omics analysis reveals specific bio-geographical and functional characteristics in Inflammatory Bowel Disease intestinal mucosaECCO'20 Vienna
Year: 2020
Authors: Naama Maimon
OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel DiseaseECCO'20 Vienna
Year: 2020
Authors: Rahul Kalla
OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic studyECCO'20 Vienna
Year: 2020
Authors: Mirabella Zhao
OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel DiseaseECCO'20 Vienna
Year: 2020
Authors: Rabina Giri
OP38: Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s Disease – A multicenter randomized controlled trialECCO'20 Vienna
Year: 2020
Authors: Myrthe Jongsma
OP39: Treatment of Ulcerative Colitis with AMT-101, a novel oral Interleukin-10 Immunomodulatory fusion biologic that traffics across intestinal epitheliumECCO'20 Vienna
Year: 2020
Authors: Randall Mrsny
Orofacial Crohn'sECCO'20 Vienna
Year: 2020
Authors: Shaji Sebastian
Pathogenesis, pathology and management of serrated lesions in IBD and non-IBD (Tandem talk)5th H-ECCO IBD Masterclass
Year: 2020
Authors: Magali Svrcek, Laurent Peyrin-Biroulet
Pathology guided surgery (Tandem talk)ECCO'20 Vienna
Year: 2020
Authors: Antonino Spinelli, Paula Borralho Nunes
Perianal disease or hidradenitis suppurativa - does it matter? (Tandem talk)ECCO'20 Vienna
Year: 2020
Authors: Walter Reinisch, Harald Maier